Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Journey Medical (Nasdaq: DERM) announced that Co-Founder, President and CEO Claude Maraoui will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026.
Rhea-AI Summary
Journey Medical (Nasdaq: DERM) announced that Co-Founder, President and CEO Claude Maraoui will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026. The virtual session is scheduled for 5:00 p.m. ET, with registration via the A.G.P. conference link.
Positive
- None.
Negative
- None.
Details
News Market Reaction – FBIO
On May 20, the first trading day after this news, FBIO closed 4.74% above the previous close.
Data tracked by StockTitan Argus for the May 20 session.
Key Figures
- Conference date
- May 20, 2026
- A.G.P.’s Annual Virtual Healthcare Conference
- Fireside chat time
- 5:00 p.m. ET
- Scheduled start time for Journey Medical session
- Share price
- $2.535
- FBIO pre-news current price
- Today’s volume
- 560,663 shares
- FBIO trading volume before this news
- 20-day avg volume
- 322,651 shares
- FBIO 20-day average volume
Historical Context
-
Announced CEO fireside chat at A.G.P.’s Annual Virtual Healthcare Conference.
-
Reported Q1 2026 net income, revenue of $16.0 million, and FDA approval of ZYCUBO.
-
Journey Q1 2026 revenue growth, narrowed net loss, and positive Adjusted EBITDA.
-
Announced timing of Journey’s Q1 2026 results release and conference call.
-
CEO scheduled for fireside chat at H.C. Wainwright virtual conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.
To register for the conference, visit the A.G.P. Registration Link.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.